Pfizer Considers Facility Sale Amid GSK’s Administrative Breach in South Korea

1. Pfizer Facility Sale: Pfizer is contemplating the sale of a facility it acquired from Abzena in North Carolina in 2023. This decision comes as the company evaluates its gene therapy candidate for Duchenne muscular dystrophy.
2. GSK Penalties: GSK has been penalized by South Korea's Ministry of Food and Drug Safety for an administrative breach. The company received two penalties for violating administrative regulations.
3. Pharmaceutical Industry Developments: Other significant developments in the pharmaceutical industry include the acceleration of sales for Eisai and Biogen's Alzheimer's drug in Japan, and Verona Pharma securing up to $650 million for the potential launch of its COPD candidate ensifentrine.
4. Regulatory Updates: The European Medicines Agency (EMA) has reconfirmed that its strain selection for Covid-19 vaccines for the fall season will differ slightly from the FDA's selection.